MA50180A - Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté - Google Patents

Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté

Info

Publication number
MA50180A
MA50180A MA050180A MA50180A MA50180A MA 50180 A MA50180 A MA 50180A MA 050180 A MA050180 A MA 050180A MA 50180 A MA50180 A MA 50180A MA 50180 A MA50180 A MA 50180A
Authority
MA
Morocco
Prior art keywords
muté
kras
hla
restricted
class
Prior art date
Application number
MA050180A
Other languages
English (en)
French (fr)
Inventor
Gal Cafri
Paul F Robbins
Steven A Rosenberg
Rami Yoseph
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MA50180A publication Critical patent/MA50180A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
MA050180A 2017-09-20 2018-09-19 Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté MA50180A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762560930P 2017-09-20 2017-09-20

Publications (1)

Publication Number Publication Date
MA50180A true MA50180A (fr) 2021-05-26

Family

ID=63963389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050180A MA50180A (fr) 2017-09-20 2018-09-19 Récepteurs de lymphocytes t restreints au hla de classe ii contre kras muté

Country Status (17)

Country Link
US (3) US11306132B2 (enExample)
EP (1) EP3684799A1 (enExample)
JP (1) JP7256794B2 (enExample)
KR (2) KR102777370B1 (enExample)
CN (2) CN111201237B (enExample)
AR (1) AR112902A1 (enExample)
AU (2) AU2018335274B2 (enExample)
BR (1) BR112020005469A2 (enExample)
CA (1) CA3076339A1 (enExample)
CR (1) CR20240019A (enExample)
EA (1) EA202090652A1 (enExample)
IL (1) IL273254B2 (enExample)
MA (1) MA50180A (enExample)
MX (2) MX2020003117A (enExample)
SG (1) SG11202002425PA (enExample)
TW (1) TWI825029B (enExample)
WO (1) WO2019060349A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3127673A1 (en) 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
WO2021019476A1 (en) * 2019-07-30 2021-02-04 University Health Network Methods of identifying t cell receptors
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
BR112022015897A2 (pt) * 2020-02-14 2022-10-18 Us Health Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
CN115427057A (zh) * 2020-02-19 2022-12-02 艾琳治疗公司 靶向突变ras蛋白的分子
AU2021225872A1 (en) * 2020-02-26 2022-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted T cell receptors against RAS with G12V mutation
WO2021262829A2 (en) * 2020-06-24 2021-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against cd20
US20230272038A1 (en) * 2020-07-13 2023-08-31 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12d mutation
CA3185483A1 (en) * 2020-07-16 2022-01-20 Noam LEVIN Hla class ii-restricted drb t cell receptors against ras with g12v mutation
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
WO2022072760A1 (en) * 2020-10-02 2022-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
AU2021389909A1 (en) * 2020-11-24 2023-06-22 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
US20240325448A1 (en) * 2022-09-29 2024-10-03 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine
WO2026019786A1 (en) * 2024-07-16 2026-01-22 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
WO2026024602A2 (en) * 2024-07-22 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors against ras with g12d, g12v, g13d or q61r mutation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
ES2784261T3 (es) * 2014-11-26 2020-09-23 Us Health Receptores de células T anti-KRAS mutado
WO2017015562A1 (en) * 2015-07-22 2017-01-26 Araxes Pharma Llc Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
ES2879287T3 (es) * 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
EP4159751A1 (en) 2016-08-02 2023-04-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-kras-g12d t cell receptors

Also Published As

Publication number Publication date
AU2018335274A1 (en) 2020-04-09
SG11202002425PA (en) 2020-04-29
JP2020534828A (ja) 2020-12-03
US11306132B2 (en) 2022-04-19
WO2019060349A1 (en) 2019-03-28
TWI825029B (zh) 2023-12-11
US12304940B2 (en) 2025-05-20
JP7256794B2 (ja) 2023-04-12
US20220204584A1 (en) 2022-06-30
TW201920251A (zh) 2019-06-01
KR20250037592A (ko) 2025-03-17
CN120082603A (zh) 2025-06-03
EA202090652A1 (ru) 2020-08-21
CA3076339A1 (en) 2019-03-28
MX2024004610A (es) 2024-04-30
US20250250318A1 (en) 2025-08-07
US20190085046A1 (en) 2019-03-21
MX2020003117A (es) 2020-08-20
CN111201237B (zh) 2025-03-25
AU2025202532A9 (en) 2025-09-04
BR112020005469A2 (pt) 2020-09-29
IL273254B2 (en) 2024-09-01
KR20200051804A (ko) 2020-05-13
AU2025202532A1 (en) 2025-05-01
AR112902A1 (es) 2019-12-26
EP3684799A1 (en) 2020-07-29
KR102777370B1 (ko) 2025-03-10
IL273254A (en) 2020-04-30
AU2018335274B2 (en) 2025-02-13
CN111201237A (zh) 2020-05-26
IL273254B1 (en) 2024-05-01
CR20240019A (es) 2024-02-15

Similar Documents

Publication Publication Date Title
MA44608A (fr) Récepteurs des lymphocytes t
EP3858852C0 (en) T-CELL RECEPTOR RECOGNIZING SSX2 ANTIGEN
IL260151A (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex
MA50651A (fr) Récepteurs de lymphocytes t reconnaissant p53 mutée
MA47359A (fr) Récepteurs de lymphocytes t à appariement amélioré
PT3494133T (pt) Recetores de células t anti-kras-g12d
SG11202002425PA (en) Hla class ii-restricted t cell receptors against mutated ras
IL269002A (en) Antibodies against pd-l1
PT4219542T (pt) Recetores de células t
DK3440106T3 (da) T-cellereceptorer
DK3946621T3 (da) Mage-a4-t-cellereceptorer
PL3436079T3 (pl) Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
EP3440191A4 (en) CHIMERIC ANTIGEN RECEPTOR T-CELL COMPOSITIONS
MA49236A (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
EP3849598A4 (en) Anti-trem-2 agonist antibodies
EP3529611A4 (en) METHOD OF SCREENING B-CELL LYMPHOCYTE
SI3223850T1 (sl) Anti-mutiran kras T-celični receptorji
EP3344295A4 (en) CHIMERIC ANTI-SIALYL TN ANTIGEN RECEPTORS
MA49503A (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
IL263874A (en) Genetically modified t lymphocytes
EP3806903A4 (en) CD79A CHIMERIC ANTIGEN RECEPTORS
EP3635099A4 (en) T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR
IL276836A (en) Cd83-binding chimeric antigen receptors
EP3383893A4 (en) T CELL RECEPTORS WITH VARIABLE SINGLE DOMAIN
EP3146079A4 (en) Methods for determining lymphocyte receptor chain pairs